Sargramostim for active Crohn's disease

New England Journal of Medicine

Volumn 352, Issue 21, 2005, Pages 2193-2201

  Korzenik, Joshua R ^a   Dieckgraefe, Brian K ^b   Valentine, John F ^c,d   Hausman, Diana F ^e   Gilbert, Mark J ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Berlex Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DIZZINESS; FEMALE; FEVER; HEADACHE; HEMATOMA; HUMAN; IMMUNOSTIMULATION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPHILIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ANTIBODY PRODUCTION; DRUG EFFECT; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOCYTE COUNT; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY;

ADULT; AGED; ANTIBODY FORMATION; CROHN DISEASE; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; INTESTINAL MUCOSA; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 19444363154     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa041109     Document Type: Article

References (29)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
2. Korzenik JR, Dieckgraefe BK. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 2000;45:1121-9.
3. WiIk JN, Viney JL. GM-CSF treatment for Crohn's disease: a stimulating new therapy? Curr Opin Investig Drugs 2002;3:1291-6.
4. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4491-508.
5. Fukuzawa H, Sawada M, Kayahara T, et al. Identification of GM-CSF in Paneth cells using single-cell RT-PCR. Biochem Biophys Res Commun 2003;312:897-902.
6. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002;360: 1478-80.
7. Best WR, Becktel JM, Singleton JW. Re-derived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-6.
8. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 1989;30:983-9.
9. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
10. Kitamura T, Tojo A, Kuwaki T, et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989;73:375-80.
11. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4.
12. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004;53:542-8.
13. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-5.
14. Kimura K, Hunter SF, Thollander MS, et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 2000;75:802-6.
15. Welte T, Zhang SS, Wang T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A 2003;100:1879-84.
16. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203-7.
17. Yamanaka R, Barlow C, Lekstrom-Himes J, et al. Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. Proc Natl Acad Sci U S A 1997-94:13187-92.
18. Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002;161:Suppl 1:S88-S92.
19. Couper R, Kapelushnik J, Griffiths AM. Neutrophil dysfunction in glycogen storage disease Ib: association with Crohn's-like colitis. Gastroenterology 1991;100:549-54.
20. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
21. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
22. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-72.
23. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003;278:5509-12.
24. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's colitis. Gut 2003;52:1591-7.
25. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003;125:47-57.
26. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
27. Pelaez A, Bechara RI, Joshi PC, Brown LA, Guidot DM. Granulocyte/ macrophage colony-stimulating factor treatment improves alveolar epithelial barrier function in alcoholic rat lung. Am J Physiol Lung Cell Mol Physiol 2004;286:L106-L111.
28. Unal AE, Cevikel MH, Ozgun H, Tunger A. Effect of granulocyte-macrophage colony stimulating factor on bacterial translocation after experimental obstructive jaundice. Eur J Surg 2001;167:366-70.
29. Ramsay RG, Micallef SJ, Williams B, et al. Colony-stimulating factor-1 promotes clonogenic growth of normal murine colonic crypt epithelia cells in vitro. J Interferon Cytokine Res 2004;24:416-27.